Coronary disease & ACS

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study

J Am Coll CardiolPublished Randomised controlled trial

Primary result · Reduction in PVC burdenResult — go to the resultDifference 60.1 percentage points 95% CI 21.3–98.8

Authors' conclusion

In this phase 2 trial, varenicline significantly reduced PVC burden and nonsustained VT incidence in post-MI patients without evidence of a proarrhythmic effects.

Study context

Population
Adults with frequent premature ventricular complexes (PVCs) (≥1,000/24 h) on 72-hour ambulatory ECG monitoring at ≥4 weeks post-MIrandomised
Participants
118 adults
Comparison
Varenicline vs placebo
Primary endpoint
Percentage change in 24-hour PVC count from baseline
Follow-up
Week 6
Methodological detailsexploratory, proof-of-concept phase 2, multicentre, double-blind, placebo-controlled
  • Exploratory, proof-of-concept phase 2
  • Multicentre
  • Double-blind
  • Placebo-controlled

Primary result

Reduction in PVC burden

Difference

60.1 percentage points

95% CI 21.3–98.8

P = 0.001

Varenicline vs Placebo
difference 60.1 percentage points (95% CI 21.3–98.8); P = 0.001

As reported in the abstract

Secondary outcomes

OutcomeVareniclinePlaceboRR (95% CI)P value
Responder rate (≥50% reduction in PVC count)67.8%30.5%2.22 (1.46–3.39)P < 0.0001
Nonsustained VT incidence20.3%37.3%0.49 (0.29–0.85)P = 0.007
OutcomeVareniclinePlaceboEstimateP value
Deaths or malignant ventricular arrhythmias; adverse events0 eventsNot reported in the abstractPlacebo: not reported in the abstract

Deaths or malignant ventricular arrhythmias; adverse events

No deaths or malignant ventricular arrhythmias with varenicline
Comparable adverse event rates between groups

Original publication

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study. J Am Coll Cardiol. Published 4 March 2026. doi:10.1016/j.jacc.2025.12.090

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.